ALBRIOZA Commercial Launch

CENTAUR Adverse Events (AEs) The most common adverse events occurring with RELYVRIO (at least 15% and at least 5% greater than placebo) were diarrhea, abdominal pain, nausea, and upper respiratory tract infection. Gastrointestinal-related adverse reactions occurred throughout the study but were more frequent during the first three weeks. of treatment. Adverse Reactions Reported in More than 5% of RELYVRIO-Treated Patients with ALS and at least 5% Greater than Placebo Adverse Reaction Diarrhea* Abdominal pain* RELYVRIO (n=89) % Placebo (n=48) % 25 19 21 13 Nausea 18 13 Upper respiratory tract infection* Fatigue* 18 10 12 6 11 2 10 4 Salivary hypersecretion Dizziness 30 Incidence of Gastrointestinal Adverse Events by Study Week Proportion of Participants, % 10 20 20 30 RELYVRIO + SOC Placebo + SOC Weeks ≤3 3< Weeks 6< Weeks <6 ≤9 9 Weeks 12< Weeks 15< Weeks 18< Weeks 21< Weeks ≤12 ≤15 ≤18 ≤21 ≤24 * Adverse reaction is composed of several similar terms. Paganoni S, et al. N Engl J Med. 2020;383:919-930. Missing AMYLYX | 8

View entire presentation